Diabetes Type 1

The global incidence of hyperuricemia (HUA) is gradually increasing, and HUA poses a severe threat to human health. Between 25% and 50% of HUA patients are not effectively treated with current clinical medications due to drug contraindications or severe adverse reactions. Therefore, novel safe and effective uric acid-lowering products are needed. Fucoidan is a naturally derived polysaccharide containing sulfate groups exclusively found in brown algae. Although there are reports on the anti-HUA effects of fucoidan, the simultaneous regulation of gut microbiota by anti-HUA still needs to be fully understood. In this study, potassium oxonate (PO) and hypoxanthine-induced HUA model mice were treated with 100, 200 and 400 mg/kg fucoidan (from Laminaria japonica) for 14 days. The levels associated with HUA were quantified using assay kits to assess fucoidan intervention. 16S rRNA gene sequencing was used to analyze the effects of fucoidan in mice with HUA. The results showed that fucoidan reduced serum uric acid and urea nitrogen levels in a dose-dependent manner, and serum creatinine levels in the 200 and 400 mg/kg fucoidan groups were similar to those in the control group. It decreased the expression of uric acid metabolic protein levels of xanthine oxidase (XOD), adenosine deaminase (ADA), and glucose transporter (GLUT9) and increased ATP binding cassette subfamily G member 2 (ABCG2) protein expression. 16S rRNA gene sequencing revealed that the richness (Chao and Ace indices) and diversity (Shannon and Simpson indices) of the gut microbiota in model mice decreased, whereas supplementation with fucoidan alleviated gut microbiota dysbiosis in HUA model mice, leading to a gradual approach of α-diversity and β-diversity towards the control mice. Additionally, fucoidan supplementation significantly increased the abundance of beneficial bacteria, which are negatively correlated with the HUA-associated phenotypes, reassuring the positive effects of fucoidan on gut health. This study proposed that fucoidan can be considered a potential candidate for preventing and treating HUA.

Could long sought-after support for type 1 diabetes be as close as your kitchen cupboard? An accumulating body of scientific research appears to point in exactly that direction

(NaturalHealth365) Did you know that heartburn drugs can cause kidney damage in 50 percent of users - without any warning signs?

with over 2000 years of history in folk medicine, is known for its sweet taste and neutral nature. It is believed to nourish the lungs, strengthen the kidneys, and replenish essence and qi by acting on the lung and kidney meridians. Modern preparations of Cordyceps sinensis, such as Bailing capsules, are made from artificially fermented Cordyceps sinensis powder. Research has demonstrated the ability of Cordyceps sinensis to regulate immunity, reduce inflammation, and combat fibrosis. This article reviews the pharmacological mechanisms of Cordyceps sinensis in treating CKD, highlighting its anti-inflammatory, immunomodulatory, and renal function-enhancing effects. Clinical studies have shown that Cordyceps sinensis can lower inflammatory markers, improve kidney function, and exhibit synergistic effects when combined with angiotensin receptor blockers (ARBs) and other medications. Additionally, it is considered safe for use, making it a promising option for treating CKD in traditional Chinese medicine....

(NaturalHealth365) Learn how gout raises kidney disease risks and steps to protect your health with research-backed tips.

This is a monthly update on my glycemic management of type 1 diabetes (T1D) using lispro and Basaglar insulin injections, metformin, a ketogenic whole-food diet, and resistance and aerobic exercise…

Hyperuricemia is a metabolic disease characterized by an excessively increased level of uric acid (UA) in the blood, with an increasing prevalence and often associated with kidney damage. Gut microbiota and endotoxins of gut origin are key mediators in the gut–kidney axis that can cause renal impairment. The study was to reveal the protective effects of fucoidan on renal injury caused by hyperuricemia. The hyperuricemia model was established in C57BL/6J mice. After 10 weeks of fucoidan supplementation, we found that the levels of serum UA and creatinine were reduced, and the levels of renal tumor necrosis factor α, interleukin-18 (IL-18), IL-6, and interleukin-1β (IL-1β) were also decreased. Fucoidan inhibited the expressions of phosphorylated NF-κB p65, NLRP3, and activated caspase-1 in the kidneys. Fucoidan also regulated the expressions of Bcl-2 family proteins and decreased the activation of caspase-3, thereby exerting antiapoptotic effect. In addition, fucoidan could reduce the expressions of glucose transporter 9 (GLUT9) and urate transporter 1 (URAT1) proteins, thereby promoting the excretion of UA from the kidneys. Moreover, the protective effect of fucoidan on renal injury may be related to maintaining intestinal homeostasis. Fucoidan reduced serum lipopolysaccharide and improved the intestinal mucosal barrier function. Fucoidan decreased the abundances of Blautia, Muribaculaceae, and Dubosiella, and increased the abundances of Lactobacillus. High-dose fucoidan supplementation increased the content of butyric acid and enhanced the expression of ATP binding box transporter G2 (ABCG2) via the AMPK/AKT/CREB pathway in ileum. Conclusion: Fucoidan could protect against hyperuricemia-induced renal injury by inhibiting renal inflammation and apoptosis and modulating intestinal homeostasis in hyperuricemia mice.

PDF | Severe Acute Pancreatitis (SAP) is an acute, severe, and high-mortality special type of pancreatitis, often accompanied by gut microbiota... | Find, read and cite all the research you need on ResearchGate

(NaturalHealth365) Glyphosate exposure, from Monsanto's signature herbicide, has been linked directly to chronic kidney disease.

DuckDuckGo. Privacy, Simplified.

(NaturalHealth365) Kidney disease is a life-threatening condition that affects over 20 million Americans. Discover 4 essential nutrients.

Epoxyeicotrienoic acids (EETs) are cytochrome P450-dependent anti-hypertensive and anti-inflammatory derivatives of arachidonic acid, which are highly abundant in the kidney and considered reno-protective. EETs are degraded by the enzyme soluble epoxide ...

Various supplements have been studied to address complications from kidney problems. Read on to learn about the role of such supplements in managing kidney problems, their dosage, and safety concerns.

ely inquire. Annually, thousands of dietary supplement–induced adverse events are reported to Poison Control Centers nationwide. CAM manufacturers are not responsible for proving safety and efficacy, because the Food and Drug Administration does not regulate them. However, concern exists surrounding the safety of CAM. A literature search using MEDLINE and EMBASE was undertaken to explore the impact of CAM on renal function. English-language studies and case reports were selected for inclusion but were limited to those that consisted of human subjects, both adult and pediatric. This review provides details on dietary supplements that have been associated with renal dysfunction and focuses on 17 dietary supplements that have been associated with direct renal injury, CAM-induced immune-mediated nephrotoxicity, nephrolithiasis, rhabdomyolysis with acute renal injury, and hepatorenal syndrome. It is concluded that it is imperative that use of dietary supplements be monitored closely in all patients. Health care practitioners must take an active role in identifying patients who are using CAM and provide appropriate patient education....

Caring for someone with kidney failure at the end of life, including signs of dying from kidney failure, end-stage renal failure symptoms and how you can support someone.

Patients affected by chronic kidney disease (CKD) or end-stage renal disease (ESRD) experience a huge cardiovascular risk and cardiovascular events represent the leading causes of death. Since traditional risk factors cannot fully explain such increased ...

When you are told you have kidney failure and need treatment to stay alive, it can be a difficult time in your life. If your kidney diagnosis is new, you may feel overwhelmed, confused and angry. But

Diabetic kidney disease is a worldwide epidemic, and therapies are incomplete. Clinical data suggest that improved renal outcomes by Na+-glucose cotransporter 2 inhibitor (SGLT2i) are partly beyond their antihyperglycemic effects; however, the mechanisms are still elusive. Here, we invest …

AstraZeneca.

Over 52 weeks, dapagliflozin provided glycaemic and weight benefits, with no increased frequency of severe hypoglycaemia compared with placebo. More DKA events were reported with dapagliflozin than placebo, highlighting the importance of appropriate patient selection, education and risk-mitigation s …

Efficacy and safety results from the Japanese subpopulation of the DEPICT-2 study were generally consistent with those from the overall population, indicating that long-term dapagliflozin adjunct to insulin therapy improves glycaemic control without an increased risk of hypoglycaemia but with a risk …

Sodium glucose cotransporter-2 (SGLT2) is a sodium-dependent glucose transporter responsible for renal absorption of glucose. Dapagliflozin is an SGLT2 inhibitor used in patients with type 1 diabetes to promote urinary glucose excretion, but to date, randomized controlled trials (RCTs) to evaluate t …

Dapagliflozin as adjunctive therapy to basal-bolus regime insulin in individuals with T1DM was well tolerated and improved glycemic control with no increase in hypoglycemia. We provide further evidence of the value of this intervention.

Eight weeks of treatment with dapagliflozin did not restore hypoglycaemic awareness in people with T1DM and impaired awareness of hypoglycaemia, but ameliorated some clinical aspects.

Dapagliflozin treatment benefits to reduce HbA1c and FPG for type 1 diabetes.

The prevalence of type 1 diabetes (T1D) is increasing worldwide. T1D reduces life expectancy due to complications including cardiovascular disease. Sodium-glucose co-transporter (SGLT) inhibitors are a new class of drugs developed to treat type 2 diabetes (T2D), and now they can be used as an adjunc …

Hyperuricemia is a common metabolic disease with prominent morbidity, it can lead to many adverse effects and complications, such as chronic nephrosis…